Pediatric Grand Rounds EM - Rare Disease Day: VLCAD Deficiency Presenting as Infantile Cardiomyopathy
Starts On:
Wed, 2/24, 2021: 12:00 AM
Ends On:
Tue, 6/21, 2022: 12:00 AM
Type:
Enduring Material
Credits:
1
Description:
ESTIMATED TIME TO COMPLETE: 60 minutes
Date of Review: 2/24/21
Termination Date: 6/30/22
ACCREDITATION INFORMATION
In support of improving patient care, The Robert Larner College of Medicine at the University of Vermont is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Vermont designates this Enduring Material activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been reviewed and is acceptable for up to 1 Nursing Contact Hours.
Date of Review: 2/24/21
Termination Date: 6/30/22
ACCREDITATION INFORMATION
In support of improving patient care, The Robert Larner College of Medicine at the University of Vermont is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Vermont designates this Enduring Material activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been reviewed and is acceptable for up to 1 Nursing Contact Hours.
Objectives:
1. List the symptoms that characterize a defect in long chain fat metabolism
2. Identify effective treatment that one can begin in the ED for patients with proven or suspected VLCAD deficiency
3. Describe some of the life challenges that patients having a disorder such as VLCAD deficiency encounter
2. Identify effective treatment that one can begin in the ED for patients with proven or suspected VLCAD deficiency
3. Describe some of the life challenges that patients having a disorder such as VLCAD deficiency encounter
Additional Resources:
Contacts:
Anna Zuckerman, MD
anna.zuckerman@uvmhealth.org
Penelope Marchessault
pmarches@med.uvm.edu
Contacts:
Anna Zuckerman, MD
anna.zuckerman@uvmhealth.org
Penelope Marchessault
pmarches@med.uvm.edu
Disclosure Information:
The planners, speaker and CMIE staff have no financial disclosures. This activity did not receive any commercial support.
Mark Korson, MD - Consultant for Moderna Therapeutics, Almylam Pharmaceuticals, HemoSheat Therapeutics. Has an educational grant through Recordati Rare Diseases.
Mark Korson, MD - Consultant for Moderna Therapeutics, Almylam Pharmaceuticals, HemoSheat Therapeutics. Has an educational grant through Recordati Rare Diseases.
Topic Categories:
Pediatrics
